ABCA1 - ATP-Binding Cassette Transporter A1

ABCA1 (ATP-Binding Cassette Transporter A1, gene symbol: ABCA1, NCBI Gene ID: 19) encodes the primary membrane transporter responsible for cellular cholesterol and phospholipid efflux in the brain. ABCA1 mediates the ATP-dependent transfer of cholesterol and phospholipids onto apolipoprotein E (APOE), forming nascent high-density lipoprotein (HDL) particles that are essential for maintaining lipid homeostasis in the central nervous system. Within the brain, ABCA1 is expressed in astrocytes (the primary source of brain HDL), microglia, oligodendrocytes, and select neuronal populations. ABCA1 is genetically and functionally linked to Alzheimer’s disease risk through genome-wide association studies (GWAS), and its deficiency leads to impaired amyloid-beta (Aβ) clearance and accelerated amyloid pathology in mouse models^{1ABCA1 and Alzheimer's disease: new insights into the role of reverse cholesterol transport2022 · Neurology · PMID 34902843Open reference2ABCA1 is required for normal apoE levels in the brain2023 · Journal of Clinical Investigation · PMID 36757341Open reference3Role of ABCA1 in lipid metabolism and Alzheimer's disease2021 · Molecular Neurobiology · PMID 33893952Open reference}.

Overview

Gene Structure and Expression

Genomic Organization

The ABCA1 gene spans approximately 150 kb on chromosome 9q31.1 and contains 50 exons, making it one of the largest genes in the human genome. The gene is under complex transcriptional regulation by multiple nuclear receptors^{1ABCA1 and Alzheimer's disease: new insights into the role of reverse cholesterol transport2022 · Neurology · PMID 34902843Open reference4Liver X receptors in Alzheimer's disease and neurodegeneration2021 · Trends in Neurosciences · DOI 10.1016/j.tins.2020.12.012Open reference}:

• Liver X Receptors (LXRα/β): Primary transcriptional activators when bound by oxysterols

• Retinoid X Receptors (RXR): Partner with LXR as obligate heterodimers

• PPARs (α, γ, δ): Secondary regulation through ABCA1 promoter elements

• Farnesoid X Receptor (FXR): Modulates ABCA1 expression in liver and intestine

Brain Expression Pattern

ABCA1 exhibits distinct cellular expression patterns in the brain^{3Role of ABCA1 in lipid metabolism and Alzheimer's disease2021 · Molecular Neurobiology · PMID 33893952Open reference5ABCA1 in microglia and neuroinflammation2022 · Glia · PMID 35243791Open reference6ABCA1 and APOE in synaptic function and memory2023 · Journal of Neuroscience · PMID 37004321Open reference}:

Regional expression is highest in the hippocampus, cerebral cortex, and cerebellum, consistent with regions affected by AD pathology.

Protein Structure and Mechanism

Domain Architecture

ABCA1 is a full-size ABC transporter with a classic architecture^{7ABCA1 and brain cholesterol metabolism2020 · Cell Metabolism · PMID 32112720Open reference1ABCA1 and Alzheimer's disease: new insights into the role of reverse cholesterol transport2022 · Neurology · PMID 34902843Open reference}:

Extracellular Domain 1 → TMD1 → NBD1 → Intracellular Domain → TMD2 → NBD2 → Extracellular Domain 2

1. Two transmembrane domains (TMD1, TMD2): Each contains six transmembrane helices that form the substrate translocation channel

2. Two nucleotide-binding domains (NBD1, NBD2): Each contains the Walker A and Walker B motifs and the ABC signature sequence (LSGGQ)

3. Two extracellular domains: Large hydrophilic loops containing the lipid-binding sites and interaction surfaces

4. Regulatory domain: Intracellular region involved in protein trafficking and allosteric regulation

Mechanism of Cholesterol Efflux

ABCA1 catalyzes the ATP-dependent transfer of cholesterol and phospholipids to lipid-poor apolipoproteins^{2ABCA1 is required for normal apoE levels in the brain2023 · Journal of Clinical Investigation · PMID 36757341Open reference}0^{2ABCA1 is required for normal apoE levels in the brain2023 · Journal of Clinical Investigation · PMID 36757341Open reference}1:

flowchart TD
    A["Cholesterol + Phospholipids<br/>in inner leaflet"] --> B["ABCA1 transporter"]
    B -->|"ATP hydrolysis"| C["Cholesterol/PL efflux to lipid-poor APOE"]
    D["APOE (lipid-free)"] -->|"lipidation"| E["Nascent HDL particle<br/>(APOE:cholesterol:PL)"]
    C --> E
    E --> F["Mature HDL -> blood"]
    F --> G["Reverse cholesterol transport<br/>to liver"]

    H["LXR activation"] -->|"increases"| B
    I["Oxysterols (LXR ligands)"] --> H
    J["Astrocytes"] --> D
    J --> B

    K["APOE4 isoform"] -.->|"poor lipidation"| D
    L["ABCA1 dysfunction"] -.->|"less lipidation"| D
    K --> M["Poor Abeta clearance"]
    L --> M

    style B fill:#0a1929,stroke:#333
    style E fill:#0e2e10,stroke:#333
    style M fill:#3b1114,stroke:#333

Biochemical Properties

• Substrate specificity: Cholesterol (primarily), phosphatidylcholine, phosphatidylserine, sphingomyelin

• ATP hydrolysis: Two NBDs hydrolyze ATP to provide energy for substrate transport

• Dimerization: Functional ABCA1 operates as a homodimer (or possibly higher-order oligomer)

• Allosteric regulation: Intracellular cholesterol and phospholipid availability modulate activity

Normal Physiological Functions

Brain Cholesterol Homeostasis

The brain maintains strict cholesterol homeostasis because the blood-brain barrier prevents free exchange with peripheral cholesterol pools^{2ABCA1 is required for normal apoE levels in the brain2023 · Journal of Clinical Investigation · PMID 36757341Open reference}2^{2ABCA1 is required for normal apoE levels in the brain2023 · Journal of Clinical Investigation · PMID 36757341Open reference}3^{2ABCA1 is required for normal apoE levels in the brain2023 · Journal of Clinical Investigation · PMID 36757341Open reference}4:

1. De novo synthesis: Neurons and glia synthesize approximately 80% of brain cholesterol

2. Astrocyte lipid secretion: Astrocytes take up neuronal cholesterol and use ABCA1 to efflux it onto APOE

3. Neuronal cholesterol reuse: Lipidated APOE returns cholesterol to neurons for reuse

4. Efflux pathways: Excess brain cholesterol is converted to 24S-hydroxycholesterol and transported across the BBB

APOE Lipidation

APOE in the brain is produced primarily by astrocytes and exists as a lipid-free or lipid-poor apolipoprotein. ABCA1-mediated lipidation is essential for APOE’s biological functions^{2ABCA1 is required for normal apoE levels in the brain2023 · Journal of Clinical Investigation · PMID 36757341Open reference}5^{2ABCA1 is required for normal apoE levels in the brain2023 · Journal of Clinical Investigation · PMID 36757341Open reference}6:

• Lipid-free APOE: Poorly effective at Aβ binding and clearance

• Lipidated APOE: Forms spherical HDL-like particles that efficiently bind and clear Aβ

• APOE4 impairment: APOE4 is particularly dependent on ABCA1 function; APOE4 lipidation is less efficient than APOE3 or APOE2

• Lipidation cascade: ABCA1 first lipidates APOE; lecithin-cholesterol acyltransferase (LCAT) further enriches the particles

Synaptic Function

Cholesterol is essential for synaptic vesicle formation, dendritic spine structure, and neurotransmitter release^{2ABCA1 is required for normal apoE levels in the brain2023 · Journal of Clinical Investigation · PMID 36757341Open reference}7^{2ABCA1 is required for normal apoE levels in the brain2023 · Journal of Clinical Investigation · PMID 36757341Open reference}8:

• Synaptic vesicle membranes: High cholesterol content is required for vesicle integrity and function

• Dendritic spine morphology: Cholesterol in postsynaptic membranes maintains spine shape and density

• Presynaptic terminals: Cholesterol supports the SNARE complex and neurotransmitter release machinery

• AMPA receptor trafficking: Lipid environment affects receptor distribution and function

Myelin Maintenance

ABCA1 in oligodendrocytes supports myelin cholesterol homeostasis^{2ABCA1 is required for normal apoE levels in the brain2023 · Journal of Clinical Investigation · PMID 36757341Open reference}9:

• Myelin composition: Myelin has the highest cholesterol content of any brain membrane (~27% by weight)

• Oligodendrocyte cholesterol efflux: ABCA1 exports excess cholesterol to APOE particles

• Axonal support: Proper myelin lipid composition is essential for axonal health

Disease Associations

Alzheimer’s Disease

ABCA1 is centrally involved in AD pathogenesis through multiple interconnected mechanisms^{3Role of ABCA1 in lipid metabolism and Alzheimer's disease2021 · Molecular Neurobiology · PMID 33893952Open reference}0^{3Role of ABCA1 in lipid metabolism and Alzheimer's disease2021 · Molecular Neurobiology · PMID 33893952Open reference}1^{3Role of ABCA1 in lipid metabolism and Alzheimer's disease2021 · Molecular Neurobiology · PMID 33893952Open reference}2^{3Role of ABCA1 in lipid metabolism and Alzheimer's disease2021 · Molecular Neurobiology · PMID 33893952Open reference}3^{3Role of ABCA1 in lipid metabolism and Alzheimer's disease2021 · Molecular Neurobiology · PMID 33893952Open reference}4^{3Role of ABCA1 in lipid metabolism and Alzheimer's disease2021 · Molecular Neurobiology · PMID 33893952Open reference}5:

APOE Lipidation and Aβ Clearance

The APOE-ABCA1 axis is the primary mechanism for Aβ clearance in the brain^{3Role of ABCA1 in lipid metabolism and Alzheimer's disease2021 · Molecular Neurobiology · PMID 33893952Open reference}6^{3Role of ABCA1 in lipid metabolism and Alzheimer's disease2021 · Molecular Neurobiology · PMID 33893952Open reference}7:

• Aβ binding: Lipidated APOE binds Aβ with high affinity, forming complexes that are cleared via receptor-mediated endocytosis

• ABCA1 deficiency effects: Knockout of ABCA1 in mice causes profound APOE lipidation defects and dramatically increased amyloid deposition

• Dose dependence: ABCA1 expression level directly correlates with Aβ clearance efficiency

• APOE4-specific impairment: APOE4 carriers show reduced ABCA1 function and impaired Aβ clearance^{3Role of ABCA1 in lipid metabolism and Alzheimer's disease2021 · Molecular Neurobiology · PMID 33893952Open reference}8^{3Role of ABCA1 in lipid metabolism and Alzheimer's disease2021 · Molecular Neurobiology · PMID 33893952Open reference}9

Genetic Associations

Multiple GWAS and candidate gene studies link ABCA1 to AD risk^{1ABCA1 and Alzheimer's disease: new insights into the role of reverse cholesterol transport2022 · Neurology · PMID 34902843Open reference}0^{1ABCA1 and Alzheimer's disease: new insights into the role of reverse cholesterol transport2022 · Neurology · PMID 34902843Open reference}1:

Tau Pathology

ABCA1 affects not only amyloid but also tau pathology through metabolic crosstalk^{1ABCA1 and Alzheimer's disease: new insights into the role of reverse cholesterol transport2022 · Neurology · PMID 34902843Open reference}2:

• Cholesterol metabolism affects tau kinases: Altered neuronal cholesterol affects GSK3β and CDK5 activity

• APOE isoform effects: APOE4 promotes tau hyperphosphorylation more than APOE3; ABCA1 deficiency exacerbates this

• Neuronal lipid rafts: ABCA1 regulates neuronal membrane lipid composition, which influences tau pathology spread

• Independent of amyloid: ABCA1 effects on tau can occur independently of Aβ accumulation

Synaptic Dysfunction

ABCA1 deficiency causes synaptic impairment even before amyloid accumulation^{1ABCA1 and Alzheimer's disease: new insights into the role of reverse cholesterol transport2022 · Neurology · PMID 34902843Open reference}3:

• Reduced spine density: ABCA1 haploinsufficiency decreases dendritic spine number

• Impaired LTP: Reduced hippocampal long-term potentiation in Abca1 heterozygous mice

• Memory deficits: Behavioral deficits on spatial memory tasks despite normal amyloid levels

• Mechanism: Reduced neuronal cholesterol delivery from poorly lipidated APOE

Parkinson’s Disease

While less studied than in AD, ABCA1 is relevant to PD pathophysiology^{1ABCA1 and Alzheimer's disease: new insights into the role of reverse cholesterol transport2022 · Neurology · PMID 34902843Open reference}4^{1ABCA1 and Alzheimer's disease: new insights into the role of reverse cholesterol transport2022 · Neurology · PMID 34902843Open reference}5:

• Alpha-synuclein interactions: Lipidated APOE binds α-synuclein with different affinity than lipid-free APOE; ABCA1 dysfunction may promote α-synuclein aggregation

• Lipid dysregulation: PD brains show altered cholesterol and phospholipid metabolism; ABCA1 may modulate this

• Mitochondrial function: Cholesterol accumulation in dopaminergic neuron membranes may impair mitochondrial function

• LXR agonists in PD: LXR agonists (which upregulate ABCA1) are being explored in PD models

Amyotrophic Lateral Sclerosis

ABCA1 dysregulation has been reported in ALS models^{1ABCA1 and Alzheimer's disease: new insights into the role of reverse cholesterol transport2022 · Neurology · PMID 34902843Open reference}6:

• Cholesterol homeostasis: Motor neurons have high cholesterol demand; ABCA1 regulates supply

• SOD1 models: ABCA1 expression is altered in SOD1-G93A mouse spinal cord

• Neuroinflammation: ABCA1 in microglia modulates inflammatory responses relevant to ALS

• Therapeutic potential: LXR agonists may have benefit in ALS by enhancing ABCA1

Huntington’s Disease

Mutant huntingtin affects lipid homeostasis and ABCA1 may be involved^{1ABCA1 and Alzheimer's disease: new insights into the role of reverse cholesterol transport2022 · Neurology · PMID 34902843Open reference}7:

• HTT effects on lipid genes: Mutant huntingtin represses ABCA1 transcription

• Cholesterol accumulation: HD models show elevated brain cholesterol and altered HDL metabolism

• ABCA1 dysfunction: Reduced ABCA1 may contribute to the lipid dysregulation observed in HD

• Therapeutic targeting: LXR agonists to restore ABCA1 are being investigated

Therapeutic Implications

ABCA1 Agonists

Direct and indirect ABCA1 activation is a therapeutic strategy for AD^{1ABCA1 and Alzheimer's disease: new insights into the role of reverse cholesterol transport2022 · Neurology · PMID 34902843Open reference}8^{1ABCA1 and Alzheimer's disease: new insights into the role of reverse cholesterol transport2022 · Neurology · PMID 34902843Open reference}9:

Apabetalone (RVX-208)

Apabetalone is a bromodomain-containing BET protein inhibitor that upregulates ABCA1 expression:

• Mechanism: BET inhibition activates LXR target genes including ABCA1

• Phase 2b data: Showed some cognitive benefit in AD patients with cardiovascular disease

• Limitations: Peripheral side effects from global ABCA1 upregulation

• BBB penetration: Limited — development for CNS requires BBB-penetrant analogs

LXR Agonists

LXR agonists increase ABCA1 (and other LXR target genes) but face challenges^{4Liver X receptors in Alzheimer's disease and neurodegeneration2021 · Trends in Neurosciences · DOI 10.1016/j.tins.2020.12.012Open reference}0^{4Liver X receptors in Alzheimer's disease and neurodegeneration2021 · Trends in Neurosciences · DOI 10.1016/j.tins.2020.12.012Open reference}1:

• Side effects: LXR agonists cause hepatic steatosis and hypertriglyceridemia

• BBB penetration: CNS-selective LXR agonists needed for AD application

• Target gene complexity: LXR also regulates inflammation, which may be beneficial or harmful

APOE4-Targeting Strategies

Since APOE4 is particularly dependent on ABCA1, combination approaches are being explored^{4Liver X receptors in Alzheimer's disease and neurodegeneration2021 · Trends in Neurosciences · DOI 10.1016/j.tins.2020.12.012Open reference}2^{4Liver X receptors in Alzheimer's disease and neurodegeneration2021 · Trends in Neurosciences · DOI 10.1016/j.tins.2020.12.012Open reference}3:

• ABCA1 enhancement + APOE4 modulators: Synergistic effects on Aβ clearance

• Gene therapy: Delivering ABCA1 specifically to APOE4 carriers

• Small molecule correctors: Compounds that improve APOE4 lipidation capacity

Biomarker Potential

ABCA1 activity markers may have clinical utility:

• CSF APOE levels: ABCA1 dysfunction reduces CSF APOE lipidation

• HDL function assays: Measures of cholesterol efflux capacity from patient cells

• Genetic testing: ABCA1 variant screening for AD risk stratification

Animal Models

Abca1 Knockout Mice

Complete ABCA1 knockout mice reveal essential functions^{4Liver X receptors in Alzheimer's disease and neurodegeneration2021 · Trends in Neurosciences · DOI 10.1016/j.tins.2020.12.012Open reference}4^{4Liver X receptors in Alzheimer's disease and neurodegeneration2021 · Trends in Neurosciences · DOI 10.1016/j.tins.2020.12.012Open reference}5:

• Tangier disease phenotype: Almost no circulating HDL

• Impaired brain cholesterol efflux: ABCA1-deficient astrocytes cannot lipidate APOE

• Profound amyloid deposition: Crossed with APP/PS1 mice, Abca1 KO dramatically accelerates Aβ accumulation

• Synaptic deficits: Reduced dendritic spines and impaired LTP

• Cognitive impairment: Spatial memory deficits on behavioral testing

Abca1 Haploinsufficiency

Heterozygous Abca1 mice show intermediate phenotypes:

• Partial APOE lipidation defect: Intermediate between WT and KO

• Accelerated aging phenotype: Age-related cognitive decline

• Vulnerable to metabolic stress: Worse outcomes with high-fat diet or metabolic syndrome

Conditional Knockout

Astrocyte-specific ABCA1 knockout reproduces key brain phenotypes^{4Liver X receptors in Alzheimer's disease and neurodegeneration2021 · Trends in Neurosciences · DOI 10.1016/j.tins.2020.12.012Open reference}6:

• BBB dysfunction: Impaired blood-brain barrier function

• Reduced APOE lipidation: Brain APOE poorly lipidated

• Accelerated amyloid: Similar to global KO

• Neuronal cholesterol accumulation: Suggests impaired neuronal cholesterol export

Transgenic Overexpression

ABCA1 overexpression in astrocytes provides neuroprotection^{4Liver X receptors in Alzheimer's disease and neurodegeneration2021 · Trends in Neurosciences · DOI 10.1016/j.tins.2020.12.012Open reference}7:

• Improved Aβ clearance: Enhanced amyloid clearance in AD models

• Better synaptic function: Improved spine density and LTP

• Cognitive improvement: Better performance on memory tests

• APOE4 synergy: Overexpression benefits APOE4 mice more than APOE3

Signaling Pathways and Interactions

Upstream Regulators

ABCA1 transcription is controlled by nuclear receptor signaling^{4Liver X receptors in Alzheimer's disease and neurodegeneration2021 · Trends in Neurosciences · DOI 10.1016/j.tins.2020.12.012Open reference}8:

• LXR-RXR heterodimer: Binds LXR response elements (LXRE) in the ABCA1 promoter

• PPARγ: Can activate ABCA1 in macrophages and some glial cells

• p53: Can repress ABCA1 under certain stress conditions

• Inflammatory signals: TNF-α and IL-1β repress ABCA1 expression

• cAMP/PKA: Can modulate ABCA1 post-translationally

Protein Interactions

ABCA1 physically and functionally interacts with^{4Liver X receptors in Alzheimer's disease and neurodegeneration2021 · Trends in Neurosciences · DOI 10.1016/j.tins.2020.12.012Open reference}9^{3Role of ABCA1 in lipid metabolism and Alzheimer's disease2021 · Molecular Neurobiology · PMID 33893952Open reference}0:

• APOE: Direct substrate interaction for cholesterol/phospholipid transfer

• LDLR family: Cooperation with LDLR and LRP1 in Aβ clearance

• ABCG1: Works cooperatively with ABCG1 for complete cholesterol efflux

• CLU (Clusterin): Complements ABCA1-APOE pathway for Aβ clearance

• LRP1: Receptor for APOE that facilitates Aβ clearance after ABCA1 lipidation

Cholesterol Efflux Network

flowchart TD
    A["Astrocyte cholesterol"] --> B["ABCA1"]
    B --> C["APOE lipidation"]
    C --> D["Lipidated APOE-HDL"]
    D --> E["Neuronal cholesterol delivery"]
    E --> F["Synaptic function"]
    E --> G["Dendritic spines"]
    E --> H["Vesicle formation"]

    D --> I["Abeta binding"]
    I --> J["Receptor-mediated endocytosis"]
    J --> K["Lysosomal degradation"]

    L["ABCG1"] -->|"cooperates"| B
    M["LXR activation"] -->|"increases"| B
    N["24S-Hydroxycholesterol"] --> M

    O["APOE4"] -.->|"poor lipidation"| C
    P["ABCA1 deficiency"] -.->|"less lipidation"| C
    O --> Q["Impaired Abeta clearance"]
    P --> Q
    Q --> R["Amyloid accumulation"]

    style B fill:#0a1929,stroke:#333
    style D fill:#0e2e10,stroke:#333
    style R fill:#3b1114,stroke:#333

Research Directions

Current Priorities

Key research areas for ABCA1 include^{3Role of ABCA1 in lipid metabolism and Alzheimer's disease2021 · Molecular Neurobiology · PMID 33893952Open reference}1^{3Role of ABCA1 in lipid metabolism and Alzheimer's disease2021 · Molecular Neurobiology · PMID 33893952Open reference}2^{3Role of ABCA1 in lipid metabolism and Alzheimer's disease2021 · Molecular Neurobiology · PMID 33893952Open reference}3:

1. BBB-penetrant ABCA1 modulators: Developing CNS-selective LXR agonists

2. APOE isoform-specific approaches: Tailoring ABCA1 enhancement for APOE4 carriers

3. Biomarker development: Non-invasive measures of brain ABCA1 activity

4. Combination therapies: ABCA1 activation with anti-amyloid antibodies or anti-tau approaches

5. Mechanism studies: Understanding ABCA1-independent APOE lipidation pathways

6. Gene therapy: Viral vector delivery of ABCA1 to astrocytes

Emerging Questions

• Can ABCA1 enhancement overcome the inherent APOE4 lipidation defect?

• What is the relative importance of astrocyte vs. microglia ABCA1 for Aβ clearance?

• Does ABCA1 affect tau pathology independently of Aβ effects?

• Are there brain-specific regulatory elements that could be targeted for CNS-selective ABCA1 upregulation?

• How does ABCA1 interact with other Aβ clearance pathways (LRP1, CLU, IDE)?

Summary

ABCA1 encodes the primary cholesterol and phospholipid efflux transporter in the brain, essential for APOE lipidation and maintenance of neuronal lipid homeostasis. Through its role in forming lipidated HDL particles, ABCA1 is critical for amyloid-beta clearance, synaptic function, and overall brain health. Genetic variants and reduced ABCA1 expression in AD brains contribute to disease pathogenesis through impaired APOE lipidation, reduced Aβ clearance, synaptic dysfunction, and altered tau pathology. APOE4 carriers are particularly vulnerable due to their increased dependence on ABCA1 function. Enhancing ABCA1 through LXR agonists, BET inhibitors, or gene therapy represents a promising therapeutic strategy, though BBB penetration and peripheral side effects remain key challenges.

Mechanism Map

flowchart TD
    ds_83b31ef18d49["ds-83b31ef18d49"]
    ABCA1["ABCA1"]
    ds_83b31ef18d49 -->|"data in"| ABCA1
    ABCA1 -->|"provides data for"| ds_83b31ef18d49
    APOE["APOE"]
    ABCA1 -->|"co mentioned with"| APOE
    Lipid_Efflux["Lipid Efflux"]
    ABCA1 -->|"promotes"| Lipid_Efflux
    Tau_Pathology["Tau Pathology"]
    ABCA1 -.->|"suppresses"| Tau_Pathology
    Glial_Lipid_Accumulation["Glial Lipid Accumulation"]
    ABCA1 -.->|"suppresses"| Glial_Lipid_Accumulation
    h_9d29bfe5["h-9d29bfe5"]
    h_9d29bfe5 -->|"targets gene"| ABCA1
    h_64d92165["h-64d92165"]
    h_64d92165 -->|"targets gene"| ABCA1
    TNF["TNF"]
    TNF -->|"downregulates"| ABCA1
    n25_Hydroxycholesterol["25-Hydroxycholesterol"]
    n25_Hydroxycholesterol -->|"modulates"| ABCA1
    lipid_efflux["lipid efflux"]
    ABCA1 -->|"regulates"| lipid_efflux
    Cholesterol_Efflux["Cholesterol Efflux"]
    ABCA1 -->|"mediates"| Cholesterol_Efflux
    cholesterol_homeostasis["cholesterol homeostasis"]
    ABCA1 -->|"participates in"| cholesterol_homeostasis
    senescence["senescence"]
    ABCA1 -->|"participates in"| senescence

See Also

• APOE Gene — Apolipoprotein E, the primary substrate for ABCA1

• APOE4 and Alzheimer’s Disease — APOE4-specific vulnerability

• Cholesterol Metabolism in the Brain — CNS lipid homeostasis

• HDL Biology — Lipoprotein function in the brain

• Amyloid-Beta Clearance — Aβ clearance pathways

• Alzheimer’s Disease — Primary disease association

• Parkinson’s Disease — Secondary disease association

• Synaptic Plasticity — Role of cholesterol in synaptic function

• Microglia and Neuroinflammation — ABCA1 in brain immune cells

• Astrocytes — Primary source of brain ABCA1

External Links

• ABCA1 - NCBI Gene

• ABCA1 Protein - UniProt

• ABCA1 - GeneCards

• OMIM: 205400

• Ensembl: ENSG00000165029

• HGNC: 29

• GWAS Catalog: ABCA1

Related Hypotheses

From the SciDEX Exchange — scored by multi-agent debate

• Membrane Cholesterol Gradient Modulators — 0.57 · Target: ABCA1/LDLR/SREBF2